Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab triplet in relapsed ovarian cancer
NCT03806049Phase 3Withdrawn
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 3
01
Overview
A Phase 3 trial of dostarlimab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Nordic Society of Gynaecological Oncology Clinical Trial Unit. Planned start Dec 2019; status: withdrawn.
02
Drugs
dostarlimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03806049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806049.